Cell & Gene Therapies in Dermatology Disorders: Therapeutic Analysis

Currently, there are seven marketed cell and gene therapies (CGTs) for various dermatology disorders. This includes one gene therapy and six cell therapies. Biosolution's KeraHeal, indicated for the treatment of burns in pediatric and adult patients, was the first autologous keratinocyte cell-based therapy to receive approval in the dermatology market in 2006, by the Ministry of Food and Drug Safety (MFDS) in South Korea. Over the past decade, there has been an increase in the number of approved CGTs for dermatology disorders. However, the market has also faced several discontinuations of CGT development programs, especially in the EU, primarily driven by the high cost of development, lack of funding, and safety concerns.

Both marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic therapy.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the CGT in Dermatology market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact Dermatology disease targeting CGT therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective unterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.